

The Homologous Relationship of Ophidian Amino Acids, as it Would Apply to a DNA-Based Vaccine in Humans

Tim Friede

Part of my responsibility with this vaccine was to track down the complete DNA sequences of snake venom fractions that I was to use on myself, or humans in the field. This was a large task due to the plethora of deleterious fractions that venomous snakes have. There are about 500 species of venomous snakes, and the biggest killers are Elapidae/Viperidae(3). Of those, only a handful are dangerous to humans due to human populations that encounter these snakes, venom toxicity, aggression, etc. Certain venomous snakes can have over 40-50 deleterious fractions that can be harmful to humans. How do you pick from this selection to choose the ones that we will use for a DNA-based vaccine protocol? Two more very important goals I aimed at achieving were finding what other snake venom fractions had similar amino acid sequences, and what amino acids were involved in the epitope for IgG binding and possible cross-reactivity, that might be important with developing the DNA-based vaccine for humans. I felt a thorough epitope mapping mission was in order to reveal these critical IgG binding sites to maybe make a better vaccine.

This is where I turned to a super article by J.P. Chippaux on The Global Evaluation of Snakebites(1). His in depth article helped me focus in on the major culprits of snakebite death throughout the world. This gave me a great picture for the overall crisis of snakebite death. I couldn't start to build my theoretical case for a DNA-based vaccine without the appropriate fractions that would save the most amount of lives, fingers, hands, legs, etc. His study showed these results on snakebite death throughout the world. Europe(30 deaths), Middle East(100 deaths), USA/Canada(15 deaths), Central/South America(5,000 deaths), Africa(20,000 deaths), Asia(100,000 deaths), and Oceania(200)(1).

At this point I studied the major killers in these parts of the world and made a detailed list of them to further break down the schematic of death. South American deaths a year are due to Bothrops mainly(atrox, asper, jararaca, etc.). Crotalus durissus also comes into play, but Bothrops is the major killer.

Africa is next with many genera that can kill. Echis has 9 spp. that cause human deaths(coloratus, hughesi, jageri, leucogaster, megalocephalus, ocellatus, omanensis, and pyramidum[3]). Bitis has 16 species that cause human deaths(albanica, arietans, armata, atropos, caudalis, cornuta, gabonica, heraldica, inornata, nasicornis, parviocula,

peringueyi, rubida, schneideri, worthington, xeropaga[3]). Naja has 10 spp that cause human deaths(haje, melanoleuca, mossambica, katiensis, pallida, nigricollis, nivea, anchietae, annulifera, and nubiae[3]). The Dendroaspis genus has four species that cause human deaths (angusticeps, jamesoni, polylepis, and viridis[3]).

Asia has the biggest ratio of snakebite death due to the big four(plus others). Indian cobra, common krait, russell's viper, and the saw-scaled viper. The cobras consist of Naja(atra, kaouthia, mandalayensis, naja, oxiana, philippinensis, sagittifera, samaras, siamensis, sputatrix, and sumatrana[3]). Bungarus has (andamanensis, bungaroides, caeruleus, candidus, ceylonicus, fasciatus, flaviceps, lividus, magnimaculatus, niger, sindanus, Lewinski[3]). Daboia russelii, and Echis carinatus also have very large roles in snakebite death in Asia.

At this time I focused on the major killers, with the major fractions that cause death or disability. I've chosen these genera, with these certain fractions that cause the most harm.

I broke it down into these major families that create the most trouble: SVMP(causes haemorrhage), PLA2(pro/anti coagulant), CTL(platelet/coagulation problems) alpha three-finger postsynaptic neurotoxins(inhibits nAChR and produces peripheral paralysis at the NMJ),PLA2 presynaptic beta neurotoxins(blocks acetylcholine release at the nerve terminal[2,4]). There are many more, but this is a strong representation of deleterious fractions from multiple genera as a comparison. The Harrisson paper also uses SVMP, PLA2 and CTL as a amino acid comparison(2).

SVMP Amino Acid Comparisons


Kenyan Echis carinatus(ecarin, Q90495)616aa, mature protein 426aa(90% identity with Echis ocellatus fraction EoMP06[4]).



(ref. 5, 6)

No.	Start Position	End Position	Peptide	Peptide Length
1	26	30	GNVND	5
2	33	34	VV	2
3	39	57	VTALPKGAVQQPEQKYEDA	19
4	63	65	EVK	3
5	79	103	LFSEDYSETHYSSDDREITT NPSVE	25
6	112	122	IQNDAESTASI	11
7	145	152	KIPDSEAH	8
8	159	184	NIENEDEAPKMCGVTQDN WESDEPIK	26
9	194	197	HERK	4
10	216	223	KYNNDSTA	8
11	264	271	STADDTLH	8
12	276	276	W	1
13	287	287	H	1
14	365	376	ESIPPPKEFSSC	12
15	378	379	YD	2
16	393	393	I	1
17	397	408	PLRKDIASPAVC	12
18	412	432	IWEEGEECDGSPADCRNP CC	21
19	438	450	KLKPGAECGNGEC	13
20	459	473	AGTECRPARDDCDVA	15
21	475	497	HCTGQSAECPRNEFQRNGQ PCLN	23

2	501	504	YCYN	4
2	522	525	ATVA	4
3				
2	548	548	Y	1
4				
2	553	560	FPCAPQDV	8
5				
2	581	600	DYSYADENKGIVEPGTKCE	20
6			D	



Reference: [Jens Erik Pontoppidan Larsen, Ole Lund and Morten Nielsen. Improved method for predicting linear B-cell epitopes. Immunome Res. 2006; 2: 2.](#)

MIQILLVIICLAVFPYQGCSIILGSGNVNDYEVVYPQKVTALPK
 GAVQQPEQKYEDAMQYEFEVKGEVVLHLEKNKELFSEDYSETHYSSDDREITT
 NPSV
 EDHCYYHGRIQNDAESTASISACNGLKGHFKLGRGETYFIEPLKIPDSEAHAVYKY
 ENI
 ENEDEAPKMCGVTQDNWESEPIKKTGLGLIVPPHERKFEKKFIELVVVVDHSMV
 TKYN
 NDSTAIRTWIYEMLNTVNEIYLPFNIRVALVGLFWCNGDLINVTSTADDTLHSF
 GEW
 RASDLLNRKRHDHAQLLTNVTLDHSTLGITFVYGMCKSDRSVELILDYSNITFNM
 AYI
 IAHEMGHSLGMLHDTKFCTCGAKPCIMFGKESIPPPKEFSSCSYDQYNKYLLKYN
 PKC
 ILDPPLRKDIASPAVCGNEIWEEGEECDGSPADCRNPCCDAATCKLKPGAECGN
 GEC
 CDKCKIRKAGTECRPARDDCDVAEHCTGQSAECPRNEFQRNGQPCLNNSGYCY
 NGDCP
 IMLNQCIALFSPSATVAQDSCFQRNLQGSYYGYCTKEIGYYGKRFPAPQDVKC
 GRLY
 CLDNSFKKNMRCNDYSYADENKGIVEPGTKCEDGKVCINRKCVDVNTAY


Daboia russellii(RVV-X, Q7LZ61),429aa(4)



(ref. 5, 6)

No.	Start Position	End Position	Peptide	Peptide Length
1	26	34	KCNSTATNT	9
2	72	79	SSADETLN	8
3	83	84	EW	2
4	94	94	S	1
5	130	136	QEQGNRN	7
6	173	179	LSDQPSK	7
7	207	240	RKDIVSPVCGNEIWEEGEECDGSP ANCQNPCC	34


8	246	254	KLKPGAECG	9
9	275	314	RARDECDVPEHCTGQSAECPRDQLQ QNGKPCQNNRGYCYN	40
1	333	335	NVA	3
1	339	339	C	1
1	345	346	KG	2
1	353	367	RKENGRKIPCAPQDV	15
1	378	385	SPRNKNPC	8
1	396	411	KGMVDPGTKCEDGKVC	16



LVSTSAQFNKIFIELVIIVDHSMAKKCNST ATNTKIYEIVN
SANEIFNPLNIHVTLIGVE FWCDRDLINVTSSADETLNSFG

EWRASDLMTRKSHDNALLFTDMRFDLNTLGITFLAGMCQ
 AYRSVEIVQEQQGNRNFKTA VIMAHESHN LGMYHDGKN
 CICNDSSCVMSPVLS DQPSKL FSNCSIHDYQRYLTRYKPK
 CIFNPPLRKDI VSPPVCGNEIWEEGEECD CGSPANQNPC
 CDAATCKLKPGAECGNGLCCYQCKIKTAGTV CRTRRARD
 ECDVPEHCTGQSAECPRDQLQQNGKPCQNNRGYCYNGD
 CPIMRNQCISLFGS RANVAKDSCFQENLKGSYYGYCRKE
 NGRKI PCAPQDVKCGRLFCLNNSPRNKNPCNMHYSAMD
 QHKG MVDPGTKCEDGKVCNNKRQCVDV NTAYQSTTG


Trimeresurus gramineus(trigram in, P15503),480aa(4)



(ref. 5, 6)

N	Start Position	End Position	Peptide	Peptide Length
.				
1	28	29	LN	2
2	33	34	VV	2
3	39	54	VTALPKGAVQQKYEDA	16
4	60	62	KVN	3
5	76	77	LF	2
6	82	100	SEIHYS PDGREITAYPSVE	19
7	109	120	IENDADSTASIS	12
8	143	147	LSDSE	5
9	156	168	NVEKEDEPPKMCG	13
10	171	194	QNWESYESTKKASQLNVT PEQQR	24
11	210	220	YTKYSGNSERI	11
12	260	264	ASAPT	5
13	283	284	HD	2


1 4	299	311	IGRAPVGGMCDPK	13
1 5	342	342	H	1
1 6	344	348	DEDKC	5
1 7	360	369	SRQPSKYFSE	10
1 8	372	373	KD	2
1 9	393	408	RTDTVSTPVSGNELLE	16
2 0	410	424	GEDCDCGSPANPCCD	15
2 1	434	437	AQCG	4



MIQVLLITICLAVFPYQGSSIILESGNLNDYEVVYPEKVTALPK
GAVQQKYEDAMQYEFKVNGEPPVVLHLEKNKGLFSEDYSEIHYS PDGREITAYPS

VEDH
 CYYHGRIENDADSTASISACDGLKGFHKLQGEMYLIEPLELSDSEAHAVFKYENV
 EKE
 DEPPKMCGVTQNWESYESTKKASQLNVTPEQQRFPQRYIKLGIFVDHGMYSKYS
 GNSE
 RITKR VHQMINNINMMCRALNIVTTLSVLEIWSEKDLITVQASAPTTLTLFGAWR
 ETV
 LLNRTSHDHAQLLTATIFNGNVIGRAPVGGMCDPKRSVAIVRDHNAIVFVAVT
 MTHE
 MGHNLGMHHDDEKCNCNTCIMS KVLRSRQPSKYFSECSKDYYQTFLTNHNPQCIL
 NAPL
 RTDTVSTPVSGNELLEAGEDCDCGSPANPCCDAATCKLIPGAQCGEGLCCDQCSF
 IEE GTVCRIARGDDLDDYCNGRSAGCPRNPFHA


Bothrops jararaca(jararhagin, P30431), 571aa(90% identity with Bothrops jararaca Bothropasin, Bothrops insularis, and Crotalus d.d. SVMP P-III[4]).



(ref. 5, 6)

No	Start Position	End Position	Peptide	Peptide Length
1	1	15	ATRPKGAVQPKYEDA	15
2	21	23	KVN	3
3	37	37	L	1
4	43	62	SEIHYS PDGREITTYPPVED	20
5	70	80	IENDADSTASI	11
6	103	110	KLPDSEAH	8
7	117	129	NVEKEDEAPKMCG	13
8	133	142	NWKS YEPIKK	10
9	151	158	EQQRYDPY	8
10	170	180	GTVTKNNGDLLD	11

1 1	214	214	N	1
1 2	216	226	DKITVKPDVDY	11
1 3	244	246	KHD	3
1 4	256	261	FNGPTI	6
1 5	271	271	H	1
1 6	306	313	DTGSCSCG	8
1 7	318	318	I	1
1 8	321	329	PTISNEPSK	9
1 9	356	366	LGTDIISPVC	11
2 0	376	388	ECDCGTPENCQNE	13
2 1	398	398	K	1
2 2	400	406	GSQCGHG	7
2 3	415	444	SKSGTECRASMSECDPAEHCT GQSSECPAD	30
2 4	446	454	FHKNGQPCL	9
2 5	480	483	VYEA	4
2 6	485	496	DSCFKDNQKGNV	12
2 7	501	515	RKENGKKIPCAPEDV	15
2 8	523	532	KDNSPGQNNP	10
2 9	538	544	SNDDEHK	7
3 0	551	559	TKCADGKVC	9



Reference: [Jens Erik Pontoppidan Larsen, Ole Lund and Morten Nielsen. Improved method for predicting linear B-cell epitopes. Immunome Res. 2006; 2: 2.](#)

ATRPKGAVQPKYEDAMQYEFKVNGEPVVLHLEKNKGLFSKDYSE
 IHYSPDGREITTYPPVEDHCYHGGRIENDADSTASISACNGLKGYFKLQRETYFIE
 PL
 KLPDSEAHAVFKYENVEKEDEAPKMCQVTQNWKSYEPIKKASQLAFTAEQQRV
 DPYKY
 IEFFVVVDQGTVTKNNGDLDDKIKARMYELANIVNEIFRYLYMHVALVGLIWSN
 GDKI
 TVKPDVDYTLNSFAEWRKTDLLTRKKHDNAQLLTAIDFNGPTIGYAYIGSMCHP
 KRSV
 GIVQDYSPINLVVAVIMAHEMGHNLGIHHDGTGSCSCGDYPCIMGPTISNEPSKFFS
 NC
 SYIQCWDFIMNHNPECIINEPLGTDIISPPVCGNELLEVGEEDCGTPENCQNECC
 DA
 ATCKLKSGSQCGHGDCCEQCKFSKSGTECRASMSECDPAEHCTGQSSECPADV
 HKNG
 QPCLDNYGYCYNGNCPIMYHQYALFGADVYEAEDSCFKDNQKGNYYGYCRK
 ENGGKI
 PCAPEDVKCGRLYCKDNSPGQNNPCKMFYSNDDEHKGMVLPGTKCADGKVC
 NGHCVD VATAY


Bitis arietans(BA-MP-2, Q4QT06), 513aa(4)



(ref. 5, 6)

No.	Start Position	End Position	Peptide	Peptide Length
1	11	21	IQNDADSTASI	11
2	45	51	LSDSEAH	7
3	58	71	NIEKEDEAPKMCGV	14
4	73	83	QTTWESDLPIK	11
5	90	96	ATSEQQK	7
6	158	166	QINVQSAPS	9
7	186	187	HD	2
8	199	204	GSTVGI	6
9	209	215	GMCDPKR	7
10	262	267	ANAGPQ	6
11	277	278	WN	2
12	290	299	KCIDNEPLRT	10
13	316	325	EECDCGPSKI	10
14	338	348	LTPGSQRSHGE	11
15	366	403	RSECDLPEHCTGQSAECPSDVFKRN GQPCQNNNGYCYN	38
16	422	423	TV	2
17	434	436	KGT	3

1 8	454	456	QDM	3
1 9	467	471	SIGNT	5
2 0	477	487	YSSQDDPDYGM	11
2 1	492	501	TKCEDGKVCN	10




Reference: [Jens Erik Pontoppidan Larsen, Ole Lund and Morten Nielsen. Improved method for predicting linear B-cell epitopes. Immunome Res. 2006; 2: 2.](#)

VEDHCYYHGRIQNDADSTASISACNGLKGFKLRGEMYLIEPLK
 LSDSEAHAVYKYENIEKEDEAPKMGVTTQTTWESDLPIKKASQLVATSEQQKVF
 NKFI
 EIYMIADNVTFNKYSRSLTAVRTRMYEILNDLNLIFIQFRIYIALIGLEIWSTNNQIN
 VQSAPSVTLRLFEDWRQNVLLKRKRHDNAQLLTVVDLDGSTVGIAPLGGMCDP
 KRSVG
 LVQDYCKSHILVAATMAHELGHSLGIKHDNVNCTCNGRPCIMSANAGPQRVFSF
 SDCS
 WNQYQKFLVDHKPKCIDNEPLRTDIVSPAFCGNHFLEKEEECDGPSKICRNPC
 NAV

TCKLTPGSQRSHGECCDQCRIKTAGTVCRERSECDLPEHCTGQSAECPDVFKR
 NGQ
 PCQNNNGYCYNGDCPILTNQCISLFGSRVTVAPDVCFTLNKKGTNKFHCRKENG
 RYIK
 CAPQDMKCGRLFCVEPSIGNTVGCKFYSSQDDPDYGMVDLGTKCEDGKVCNSN
 RECVD VNTAY


PLA2(Pro/Anticoagulant)Amino Acid Comparisons

Bitis arietans(BA-PLA2-32, Q4QT03), 138aa(100% identity with Echis ocellatus PLA2-5, and 90% identity with Bitis arietans PLA2-19[4]).



(ref. 5, 6)

No	Start Position	End Position	Peptide	Peptide Length
1	28	36	ETGRSPFPF	9
2	47	57	GGKGGPKDD TD	11
3	69	78	SMPDCSPKT D	10
4	84	84	R	1
5	94	97	GTSC	4



Reference: [Jens Erik Pontoppidan Larsen, Ole Lund and Morten Nielsen. Improved method for predicting linear B-cell epitopes. Immunome Res. 2006; 2: 2.](#)


MRTLWIVAVWLIGVEGSVIEFGTMIEETGRSPFPFYTSYGCYC
 GLGGK GKPKDDTDRCCFVHDCCYGSMPCSPKTDIYRYHRENGEIICESGTSCEK
 RIC ECDKAAAVCFRENLKTYKNKYMVYPDSLCKEESEKC

Echis pyramidum leakyi(EpIPLA2-5, P59172), 139aa(100% identity with Bitis arietans PLA2-20, 90% identity with Echis coloratus sochureki PLA2-4, and Bitis arietans PLA2-18[4]).



(ref. 5, 6)

No.	Start Position	End Position	Peptide	Peptide Length
1	26	34	KNKTGKPAM	9
2	46	57	WGGQGKPQD PSD	12
3	72	74	NCS	3
4	89	98	IICGDNDPCR	10
5	116	121	VNTYDE	6




Reference: [Jens Erik Pontoppidan Larsen, Ole Lund and Morten Nielsen. Improved method for predicting linear B-cell epitopes. Immunome Res. 2006; 2: 2.](#)

MRTLWIVAVWLMGVEGNLYQFGKMIKNKTGKPAMFYSAYGCYC
 GWGGQGKPQDPSDRCCFMHDCCYTRVNNCSPKMTLYSYRFENGDIICGDNDPC
 RKAVC ECDREAAICLGENVNTYDEKYRFYSSSYCTEESEKC

Echis coloratus(EC, Q910A0), 138aa(50% identity with over 50 different fractions[4])

No.	Start Position	End Position	Peptide	Peptide Length
1	46	56	WGGKGGKPKQ DAT	11
2	71	79	NGCDPKMGT	9
3	82	84	YSF	3
4	89	97	IVCGGDDPC	9
5	118	118	T	1




Reference: [Jens Erik Pontoppidan Larsen, Ole Lund and Morten Nielsen. Improved method for predicting linear B-cell epitopes. Immunome Res. 2006; 2: 2.](#)

MRTLWIVAVWLMGVEGHLYQFENMIYQKTGKFAIIAYSNYGCYC
 GWGGKGGKPKQDATDRCCFVHDCCYGRVNGCDPKMGTYSYSFQNGDIVCGGDDP
 CLRAVC ECDRVAANCFAENLKTYNKKYWLSSIIDCKEESEKC

Vipera palaestinae(VP, Q98996), 138aa(synergistically lethal with VP 7&8[4]).

No.	Start Position	End Position	Peptide	Peptide Length
1	26	27	NK	2
2	47	56	GGKGGKPQD AT	10
3	70	78	VNGCDPKL S	9
4	83	84	SF	2
5	89	97	IVCGDDDDPC	9
6	116	119	MNTY	4




Reference: [Jens Erik Pontoppidan Larsen, Ole Lund and Morten Nielsen. Improved method for predicting linear B-cell epitopes. Immunome Res. 2006; 2: 2.](#)

MRTLWIVAVCLMGVEGHLTQFGDMINKKTGTFGLLSYVYYGCYC
 GLGGKGGKPQDATDRCCFVHDCCYGTVNGCDPKLSTYSYSFQNGDIVCGDDDDPC
 LRAVC ECDRVAAICFGENMNTYDTKYMLHSLFDCMEESEKC


CTL Amino Acid Comparisons

Bitis arietans(CTL-1, Q6X5T5), 146aa(90% identity with Echis carinatus[Carinactivase-1], Echis carinatus sochureki[CTL-9], Echis pyramidum leaky[CTL-5][4]).



(ref. 5, 6)


N o	Start Position	End Position	Peptide	Peptide Length
1	21	25	TEADC	5
2	41	49	DEPKTWAD A	9
3	51	60	KFCSEQAN GG	10
4	68	68	R	1
5	100	103	WGWT	4
6	105	105	G	1
7	107	108	KL	2
8	111	115	EARAE	5
9	126	130	KKEWK	5



Reference: [Jens Erik Pontoppidan Larsen, Ole Lund and](#)

MGRFIFISFGLLVVFLSLSGTEADCLPDWFHYEGHCYRVFDEPK
 TWADAEKFCSEQANGGHLVSVHSRKEAGLVGVLAYQTLESPIVWMGLSKVWN
 QCDWGW TNGAKLKYEARAEESYCIHITSKKKEWKS LPCRNYGHFVCKSPA


Echis pyramidum leakeyi(CTL-1, Q6X5S3), 148aa(100% identity with Echis carinatus sochureki[CTL-1], Bitis arietans[CTL-8], Echis ocellatus[CTL-2], and 90% identity with Echis c.s.[CTL-1], Bitis arietans[CTL-6&8], and Echis ocellatus[CTL-1&2][4]).



(ref. 5, 6)

No	Start Position	End Position	Peptide	Peptide Length
1	21	23	TEA	3

2	31	37	WSGYDQN	7
3	54	54	F	1
4	58	60	QHK	3
5	102	110	WGWDGA QL	9
6	129	138	NHWSRTDC SG	10



Reference: [Reference: Jens Erik Pontoppidan Larsen, Ole Lund and Morten Nielsen. Improved method for predicting linear B-cell epitopes. Immunome Res. 2006; 2: 2.](#)


MGRFIFVSFGLLVVFLSLSGTEAGVCCPLGWSGYDQNCYKAFEE
LMNWADA EK FCTQQHKGSHLVSLHNIAEADFVVKKIVSVLKDGVIWMGLNDV
WNECNW GWTDGAQLDYKAWNVESNCFIFKTAENHWSRTDCSGTHSFVCKSPA

Daboia russelli siamensis(C-Type L-3, Q4PRD0), 148aa(50% identity with over 20 different fractions[4]).



(ref. 5, 6)

No.	Start Position	End Position	Peptide	Peptide Length
1	30	34	GWSAY	5
2	36	36	Q	1
3	47	49	NWA	3
4	53	54	KF	2
5	56	56	T	1
6	58	60	QHK	3
7	102	110	WGWTDG AKL	9
8	113	117	KAWNE	5




Reference: [Reference: Jens Erik Pontoppidan Larsen, Ole Lund and Morten Nielsen. Improved method for predicting linear B-cell epitopes. Immunome Res. 2006; 2: 2.](#)


MGRFISVSFGLLVVFLSLSGTEAAFCCPSGWSAYDQNCYKVFTE
 EMNWADA EKFCTEQHKGSHLLSLHNIAEADFVLKKT LAMLKDGVIWMGLNDV
 WNECNW
 GWTDGAKLDYKAWNEG TNCFVFKIAKNHWSHMDCSSTHNFVCKFRV

Three-Finger Alpha Neurotoxin Amino Acid Comparisons

Naja naja(alpha neurotoxin, Q9PTT0), 83aa(90% identity with Naja atra Cobratoxin, Naja sputatrix alpha neuro 1,2,3,4, Naja kaouthia short neuro 1, Cobratoxin 2 precursor, Naja mossambica short neuro 1[4]).




rt Position	(ref. 5, 6) End Position	Peptide	Peptide Length	
1	26	45	NQQSSQTPTTTGCSGGETNC	2 0
2	51	68	RDHRGYRTERGCGPSVK	1 8



Reference: [Jens Erik Pontoppidan Larsen, Ole Lund and Morten Nielsen. Improved method for predicting linear B-cell epitopes. Immunome Res. 2006; 2: 2.](#)

METLLLTLVVTVIVCLDLGYTLECHNQSSQTPTTTGCSGGETN
CYKKRWRDHRGYRTERGCGCPSVKNGIEINCCTTDRCNN


Naja atra(alpha neurotoxin, P60770), 83aa(100% identity with Naja kaouthia and siamensis Cobratoxin, and 90% with 10 other Naja fractions[4]).



(ref. 5, 6)

N	Start Position	End Position	Peptide	Peptide Length
o				
.				


1	26	45	NQSSQTPTTTGCSGG ETNC	20
2	51	68	RDHRGYRTERGCGCPS VK	18



Reference: [Jens Erik Pontoppidan Larsen, Ole Lund and Morten Nielsen. Improved method for predicting linear B-cell epitopes. Immunome Res. 2006; 2: 2.](#)


MKTLLLTLVVVTIVCLDLGYTLECHNQSSQTPTTTGCSGGETN
CYKKRWRDHRGYRTERGCGCPSVKNGIEINCCTTDRCNN

Naja kaouthia(alpha neurotoxin, P60771), 83aa(100% identity with Naja atra, and 90% with 10 other Naja neuro fractions, above[4]).



(ref. 5, 6)


No	Start Position	End Position	Peptide	Peptide Length
1	26	45	NQQSSQTPTTTGCSGG ETNC	20
2	51	68	RDHRGYRTERGCGCPS VK	18



Reference: [Jens Erik Pontoppidan Larsen, Ole Lund and Morten Nielsen. Improved method for predicting linear B-cell epitopes. Immunome Res. 2006; 2: 2.](#)


MKTLLLTLVVVTIVCLDLGYTLECHNQQSSQTPTTTGCSGGGETN
CYKKRWRDHRGYRTERGCGCPSVKNGIEINCCTTDRCNN

Naja nivea(alpha long neurotoxin 1, P01390), 71aa(50% identity with over 24 other fractions[4]).



(ref 5, 6)

N o.	Start Position	End Position	Peptide	Peptide Length
1	8	16	DVTSQAC PD	9
2	44	51	TCPKVKP G	8



Reference: [Jens Erik Pontoppidan Larsen, Ole Lund and Morten Nielsen. Improved method for predicting linear B-cell epitopes. Immunome Res. 2006; 2: 2.](#)


IRCFITPDVTSQACPDGHVCYTKMWCDNFCGMRGKRVDLGCAATCPKVKPGVN
IKCCSRD
NCNPFPTKRKS

Naja nivea(alpha short neurotoxin II, P01423), 61aa(90% identity with short neurotoxin II from Naja haje haje and Naja haje annulifera[4]).



(ref. 5, 6)

No	Start Position	End Position	Peptide	Peptide Length
1	6	24	QQSSQRPTIKTCPGET NCY	19
2	29	30	RD	2
3	41	46	GCPSVK	6




Reference: [Jens Erik Pontoppidan Larsen, Ole Lund and Morten Nielsen. Improved method for predicting linear B-cell epitopes. Immunome Res. 2006; 2: 2.](#)

MICHNQQSSQPPTIKTCPGETNCYKKRWRDHRGTIIERGCGCPSVKKGVGIYCK

TNKCN
R


Presynaptic Beta Neurotoxin Amino Acid Comparisons

Bungarus multicinctus(beta PLA2 bungarotoxin A1 chain, P00617), 147aa



(ref. 5, 6)

Start Position	End Position	Peptide	Peptide Length	
1	1	1	M	1
2	21	25	NIPPH	5
3	43	51	EKTWGEYAD	9
4	57	66	GAGGSGRPID	10
5	78	96	CYGDAEKKHKCNPKTQS YS	19
6	111	111	G	1
7	133	135	YIE	3
8	137	140	HKNI	4




Reference: [Jens Erik Pontoppidan Larsen, Ole Lund and Morten Nielsen. Improved method for predicting linear B-cell epitopes. Immunome Res. 2006; 2: 2.](#)

AVCVSLLGAANIPPHPLNLFMEMIRY TIPCEKTWGEYADYGCY FT
 CGAGGSGRPIDALDRCCYVHDNCYGDAEKKHKCNPKTQSYSYKLTKRRTIICYGA
 AGTCG FT RIVCDCDRTAALCFGNSEYIEGHKNIDTARFCQ

Crotalus durissus terrificus (beta PLA2 Crotoxin, P08878), 138aa. (90% identity with Mojave rattlesnake Mtx-a[4]).

No	Start Position	End Position	Peptide	Peptide Length
1	34	35	IS	2
2	45	57	GAGGQGWPQDASD	13
3	72	99	GCDPTTDVYTYRQEDGEIVC GEDDPCGT	28
4	117	119	DTY	3



Reference: [Jens Erik Pontoppidan Larsen, Ole Lund and Morten Nielsen. Improved method for predicting linear B-cell epitopes. Immunome Res. 2006; 2: 2.](#)

MRALWIVAVLLVGVESLVEFETLMMKIAGRSGISYSSYG CYCG FT
 AGGQGWPQDASDRCCFEHDCCYAKLTGCDPTTDVYTYRQEDGEIVCGEDDPCG
 TQICEC FT DKAAAI CFRNSMDTYDYKYLQFSPENCQGESQPC


Vipera ammodytes(Ammodytoxin, P00626), 138aa(4)



(ref. 5, 6)

No	Start Position	End Position	Peptide	Peptide Length
1	29	35	TGKNPLT	7

2	46	56	VGGKGTKPKDAT	11
3	70	84	LPDCSPKTDYK YHR	15
4	94	97	GTSC	4



Reference: [Jens Erik Pontoppidan Larsen, Ole Lund and Morten Nielsen. Improved method for predicting linear B-cell epitopes. Immunome Res. 2006; 2: 2.](#)

MRTLWIVAVCLIGVEGSLLEFGMMILGETGKNPLTSYSFYGCYC
 VGGKGTKPKDATDRCCFVHDCCYGNLPDCSPKTDYKYHRENGAIVCGKGTSC
 ENRIC ECDRAAAICFRKNLKYNYIYRNYPDFLCKKESEKC

Conclusion

There are many very positive features that can be drawn from these amino acid comparisons. The complete DNA sequences are already done for all these venom fractions, which makes it easier to develop a DNA-based vaccine for human use.

The structural similarity with these fractions means that IgG raised antibodies will cross with not just different species, but different genera, in different continents. There are many 50% amino acid similarities, but the 100% and 90% fractions show that cross-reactivity will happen. The alpha neurotoxins and CTL toxins are a very good example of how similar that group is. Truly, a partial multi-continental ophidian DNA -based vaccine.

My personal opinion would be having three continental DNA vaccines for humans (partial of course at this point). South America would have the DNA-jararhagin vaccine, Africa would have the DNA-ecarin/neuro-alpha(Naja), and Asia would have the DNA-ecarin/neuro-alpha(Naja)/RVV-X(Daboia)/bungarotoxin(Bungarus).

Obviously more fractions could be added, but I feel that's a good initial mix for partial coverage. At first though, I think just zeroing in on one fraction would be the key to see if IgG acceptable titers can be achieved.

References

1) Chippaux, J.P.

[http://www.who.int/bloodproducts/publications/en/bulletin_1998_76\(5\)_515_524.pdf](http://www.who.int/bloodproducts/publications/en/bulletin_1998_76(5)_515_524.pdf)

2) Harrison, R. Development of Venom Toxin Specific Antibodies. Vaccine, V22, No. 13-14, pp. 1648-55, 2004.

3) Reptile Database. <http://www.tigr.org/reptiles/search.php>.

4) Swiss-Prot. <http://expasy.org/cgi-bin/sprot-search-ful>

5) Jurge Kopp and Torsten Schwede(2004). The SWISS-MODEL Repository of annotated 3D protein structure homology models-nucleic acids res., 32, D230-D234.

6) Schwede, T., Kopp, J., Guex, N., and Peitsch, M.C.(2003). SWISS-MODEL: An automated protein homology modeling server. Nucleic acids res., 31, 3381-3385.

